Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Trade names | Convidecia |
Other names | PakVac |
Routes of administration | Intramuscular, Nebulizer |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
DrugBank |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
AD5-nCOV, trade-named Convidecia, is a single-dose[1] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina,[2] Chile,[3] Mexico,[4] Pakistan,[5] Russia,[6] and Saudi Arabia[7] with 40,000 participants.
In February 2021, global data from Phase III trials and 101 COVID cases showed that the intramuscular version of the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[8] It has similar efficacy to the Janssen vaccine, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[9][1] Convidecia is similar to other viral vector vaccines like AZD1222, Gam-COVID-Vac, and Ad26.COV2.S.[10] Its single-dose regimen and normal refrigerator storage requirement (2° to 8 °C) could make it a favorable vaccine option for many countries.[9] It is currently under evaluation for emergency use listing by the WHO.[11] On May 19 2022, WHO issued EUL for the vaccine.[12]
A Phase I study published in The Lancet showed two doses of a nebulised version of Convidecia (inhaled through the mouth) resulted in neutralising antibody responses similar to the existing one-dose injection.[13]
Convidecia and the Pakistani version called PakVac are approved for use by some countries in Asia,[14][15][16] Europe,[17][18] and Latin America.[19][20][21] Production capacity for Ad5-NCov should reach 500 million doses in 2021. Manufacturing will take place in China,[22] with filling and finishing of the vaccine additionally also taking place in Malaysia,[16] Mexico,[23] and Pakistan.[24]
:0
was invoked but never defined (see the help page).:9
was invoked but never defined (see the help page).:10
was invoked but never defined (see the help page).NCT04526990
was invoked but never defined (see the help page).:11
was invoked but never defined (see the help page).:12
was invoked but never defined (see the help page).:13
was invoked but never defined (see the help page).arynews.tv
was invoked but never defined (see the help page).:3
was invoked but never defined (see the help page).Ashok
was invoked but never defined (see the help page).:17
was invoked but never defined (see the help page).:6
was invoked but never defined (see the help page).© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search